OBJECTIVE: There are no doubts about the clinical benefits of treatment with GnRH analogs for patients diagnosed with central precocious puberty (CPP). However, laboratory monitoring of CPP is still a matter of considerable controversy in the literature. Therefore, the main objective of this study was to evaluate the cut-off values of stimulated LH that determine gonadotrophic suppression. METHODS: Twenty-four girls, on treatment with leuprorelin acetate (LA) at 3.75 mg IM every 28 days, were studied. The clinical parameters used to indicate clinical effectiveness were regression or maintenance of sexual characteristics according to the Tanner stage, growth velocity reduction, reduction or maintenance of the difference between bone age and ...
Purpose The rapid increase in the incidence of precocious puberty in Korea has clinical and social s...
OBJECTIVE: Gonadotropin-releasing hormone analogs (GnRHa) are standard of care for the treatment ...
BACKGROUND: Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious...
Background—Central precocious puberty (CPP) is characterized by clinical, biochemical, and ra-diolog...
Copyright © 2015 H. Nur Peltek Kendirci et al. This is an open access article distributed under the ...
PurposeTo investigate the effectiveness and safety of gonadotropin-releasing hormone analogue (GnRHa...
ABSTRACT Objective: To report our experience of treating central precocious puberty (CPP) with a GnR...
Objectives: Treatment of central precocious puberty (CPP) is based on administration of GnRH agonist...
Objective: Gonadotropin stimulation test is the gold standard to document precocious puberty. Howeve...
Objective. GnRH analogues (GnRHa) are used in the treatment of central precocious puberty (CPP). The...
This study was designed to evaluate whether a single blood sample drawn after the home injection of ...
Background: Diagnosing central precocious puberty (CPP) requires an integrated approach based on cli...
Although the increasing incidence of central precocious puberty (CPP) in Korea has recently raised p...
Background: In central precocious puberty (CPP), the pulse secretion and release of gonadotropin-rel...
OBJECTIVE: Gonadotropin-releasing hormone analogs revolutionized the treatment of central precocious...
Purpose The rapid increase in the incidence of precocious puberty in Korea has clinical and social s...
OBJECTIVE: Gonadotropin-releasing hormone analogs (GnRHa) are standard of care for the treatment ...
BACKGROUND: Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious...
Background—Central precocious puberty (CPP) is characterized by clinical, biochemical, and ra-diolog...
Copyright © 2015 H. Nur Peltek Kendirci et al. This is an open access article distributed under the ...
PurposeTo investigate the effectiveness and safety of gonadotropin-releasing hormone analogue (GnRHa...
ABSTRACT Objective: To report our experience of treating central precocious puberty (CPP) with a GnR...
Objectives: Treatment of central precocious puberty (CPP) is based on administration of GnRH agonist...
Objective: Gonadotropin stimulation test is the gold standard to document precocious puberty. Howeve...
Objective. GnRH analogues (GnRHa) are used in the treatment of central precocious puberty (CPP). The...
This study was designed to evaluate whether a single blood sample drawn after the home injection of ...
Background: Diagnosing central precocious puberty (CPP) requires an integrated approach based on cli...
Although the increasing incidence of central precocious puberty (CPP) in Korea has recently raised p...
Background: In central precocious puberty (CPP), the pulse secretion and release of gonadotropin-rel...
OBJECTIVE: Gonadotropin-releasing hormone analogs revolutionized the treatment of central precocious...
Purpose The rapid increase in the incidence of precocious puberty in Korea has clinical and social s...
OBJECTIVE: Gonadotropin-releasing hormone analogs (GnRHa) are standard of care for the treatment ...
BACKGROUND: Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious...